Invivyd Begins Phase 2 Trial of VYD2311 for Long COVID and PVS
Invivyd began FLINTLOCK, a randomized, placebo-controlled Phase 2 study of VYD2311 in adults with Long COVID or Post-Vaccination Syndrome. The study plans to enroll about 130 participants, with dosing through day 60.